0001104659-23-129766.txt : 20231227
0001104659-23-129766.hdr.sgml : 20231227
20231227173528
ACCESSION NUMBER: 0001104659-23-129766
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231227
FILED AS OF DATE: 20231227
DATE AS OF CHANGE: 20231227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MARGOLIN YAEL
CENTRAL INDEX KEY: 0001868637
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39373
FILM NUMBER: 231518907
MAIL ADDRESS:
STREET 1: 4850 WEST 78TH STREET
CITY: INDIANAPOLIS
STATE: IN
ZIP: 46268
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: POINT Biopharma Global Inc.
CENTRAL INDEX KEY: 0001811764
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 850800493
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4850 WEST 78TH STREET
CITY: INDIANAPOLIS
STATE: IN
ZIP: 46268
BUSINESS PHONE: (317) 543-9957
MAIL ADDRESS:
STREET 1: 4850 WEST 78TH STREET
CITY: INDIANAPOLIS
STATE: IN
ZIP: 46268
FORMER COMPANY:
FORMER CONFORMED NAME: Therapeutics Acquisition Corp.
DATE OF NAME CHANGE: 20200511
4
1
tm2333785-11_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-12-27
1
0001811764
POINT Biopharma Global Inc.
PNT
0001868637
MARGOLIN YAEL
4850 WEST 78TH STREET
INDIANAPOLIS
IN
46268
1
0
0
0
0
Common Stock
2023-12-27
4
D
0
1710
D
0
D
Stock Option (Right to Buy)
8.47
2023-12-27
4
D
0
25000
D
2027-07-06
Common Stock
25000
0
D
Stock Option (Right to Buy)
8.31
2023-12-27
4
D
0
25614
D
2028-06-02
Common Stock
25614
0
D
Stock Option (Right to Buy)
9.12
2023-12-27
4
D
0
44749
D
2029-06-01
Common Stock
44749
0
D
This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the "Issuer"), Eli Lilly and Company (the "Parent"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 27, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the "Merger Consideration"), without interest and less any applicable tax withholding.
Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.
/s/ William L. Demers, by Power of Attorney for Yael Margolin
2023-12-27